Latest Oncogenes Stories
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
Study May Lead to More Targeted Treatments for Cancers and "Rasopathies" CINCINNATI, Nov.
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Trovagene, Inc.
Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA SAN DIEGO, Oct.
BRAF V600E assay improves determination of mutational status and allows monitoring of treatment response SAN DIEGO, Oct.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
Proceedings of the National Academy of Sciences Study Shows Ability to Create Therapeutics Targeting Critical MYC Regulator for Potential Treatment of Cancer SAN DIEGO, Aug.
A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor.
MADISON, N.J., June 10, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new cancer test service based
- To swell, as grain or wood with water.